Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2000

01-09-2000

Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells

Authors: Aye Aye Thant, Akihiro Nawa, Fumitaka Kikkawa, Yasukatu Ichigotani, Yangying Zhang, Thet Thet Sein, A.R.M. Ruhul Amin, Michinari Hamaguchi

Published in: Clinical & Experimental Metastasis | Issue 5/2000

Login to get access
Metadata
Title
Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells
Authors
Aye Aye Thant
Akihiro Nawa
Fumitaka Kikkawa
Yasukatu Ichigotani
Yangying Zhang
Thet Thet Sein
A.R.M. Ruhul Amin
Michinari Hamaguchi
Publication date
01-09-2000
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5/2000
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1010921730952

Other articles of this Issue 5/2000

Clinical & Experimental Metastasis 5/2000 Go to the issue

OriginalPaper

Different levels of TGFβ, IL-10, IFNγ and gelatinase A occur in experimental white and black metastases induced by bryostatin 1 or by phorbol ester-treated BL6T murine melanoma cells

OriginalPaper

Quercetin inhibits the invasion and mobility of murine melanoma B16-BL6 cells through inducing apoptosis via decreasing Bcl-2 expression

OriginalPaper

Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model

OriginalPaper

The role of matrilysin (MMP-7) in leukaemia cell invasion

OriginalPaper

Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation

OriginalPaper

Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits